Exploratory Study on the Prevalence of Sarcopenia-Promoting Medicines in Patients With Sarcopenia and Falls
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Prevalence of exposure to one or more sarcopenia-promoting medication
研究概览
简要总结
Sarcopenia, characterised by the loss of muscle mass and function, is a common condition among the elderly and is often associated with increased risk of falls. Certain medications, such as glucocorticoids, statins, and some antipsychotics, may exacerbate sarcopenia, leading to a higher incidence of falls. This study aims to explore the prevalence of such medicines in patients diagnosed with sarcopenia who have experienced falls. Understanding the impact of these medications on sarcopenia and fall risk can inform clinical guidelines and improve patient outcomes.
详细描述
Sarcopenia, the age-related loss of muscle mass and strength, is a recognised contributor to frailty, disability, and increased fall risk in older adults. While physical inactivity and comorbidities are known risk factors, increasing evidence suggests that certain medications - including corticosteroids, sedatives and statins - may also contribute to muscle decline. These medicines are frequently prescribed to older adults, but the extent of their use in patients with sarcopenia and falls remains poorly defined.
Falls clinics manage high-risk patients, yet there is currently limited research examining the prevalence of sarcopenia-promoting medications in this specific setting. This study addresses an important knowledge gap by estimating the prevalence of these medicines in older adults attending a secondary care falls clinic, and by exploring associations with sarcopenia and fall history.
The findings will support a better understanding of medication-related risk factors for sarcopenia and may help guide future deprescribing and medication review strategies. This aligns with current priorities in geriatric medicine to reduce inappropriate polypharmacy and improve outcomes for older adults through targeted, evidence-based prescribing.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged ≥65 years
- •Attendance at the falls clinic for a new assessment
- •Diagnosed with sarcopenia (based on the European Working Group on Sarcopenia in Older People (EWGSOP2) criteria)
- •History of falls in the past 12 months
排除标准
- •Cognitive impairment preventing consent
- •Acute medical instability
- •Enrolled in on other clinical trials.
结局指标
主要结局
Prevalence of exposure to one or more sarcopenia-promoting medication
时间窗: 6 months
Proportion of adults aged 65 years and over attending the falls clinic who are prescribed one or more sarcopenia-promoting medication. Unit of measure: % of participants.
次要结局
- Timed Up and Go Test(6 months)
- SARC-F score(6 months)
- Distribution of sarcopenia-promoting medication classes(6 months)
- Number of sarcopenia-promoting medications per participant(6 months)
- Handgrip strength(6 months)
- Gait speed(6 months)
- Association between medication burden and functional performance(6 months)
研究者
Kamaldeep Sahota
Lead Clinical Pharmacist Frailty
Medway NHS Foundation Trust